ASCENSIA DIABETES CARE COMPLETES INITIAL EUROPEAN LAUNCH OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM
Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, announces that it has successfully completed the initial European launch of the next-generation Eversense® E3 CGM System. The unique benefits of this fully-implantable, long-term CGM system are now available to people with diabetes in all launch markets across Europe, as planned.
Following the successful US launch in April 2022, the Eversense E3 CGM System has been undergoing a phased roll-out across Europe since August, in line with timings announced with the CE Mark approval in June. The system is now available in Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands, and Andorra.
Developed by Senseonics Holdings, Inc., the Eversense E3 CGM System was designed to build on the benefits of the previously available Eversense® XL CGM System but with further improvements to enhance user experience. These improvements include reduced frequency of calibration, enhanced sensor survivability and non-adjunctive use – allowing people to make treatment decisions without confirmation of glucose levels through a fingerstick test. The next-generation system offers people with diabetes:
- A long-term CGM option, with up to 6-month sensor wear duration and essentially two sensor insertion and removal procedures per year
- Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5%* demonstrated in the PROMISE Study for the duration of sensor wear
- An ability to make treatment decisions without fingerstick testing, due to non-adjunctive label
- Fewer calibrations, with primarily one calibration required per day after three weeks of use1
- A fully implantable fluorescence-based sensor, with a removable smart transmitter** that provides discreet on-body vibratory alerts and transmits data to a mobile app
- An innovative design modification to enhance sensor survivability up to 6 months
Torstein Myhre, Region Head of Europe at Ascensia Diabetes Care, commented: “We are proud to have successfully brought the Eversense E3 to Europe, where we believe it can make a big difference in the lives of people with diabetes. The Eversense E3 CGM System makes managing diabetes easier, offering unparalleled convenience and flexibility alongside exceptional accuracy. With a six-month sensor lifespan, the system frees patients from frequent sensor insertions, and its other features have been specifically designed to address improvements desired by the diabetes community. We are looking forward to bringing these benefits to more people than ever.”
People with diabetes and healthcare providers interested in learning more about Eversense E3 can find out more at www.ascensia.com/eversense.
*Overall MARD evaluated vs YSI for glucose between 40-400mg/dl
*There is no glucose data generated when the transmitter is removed.
1Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182
Notes for Editors
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see https://global.eversensediabetes.com/safety-info.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM Systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries. For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries. www.phchd.com
©2022 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
For media enquiries, please contact:
Amanda Clark, Amanda.Clark@Ascensia.com